| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/21/2009 | EP2016949A1 Novel use of g-protein-conjugated receptor and ligand thereof |
| 01/21/2009 | EP2016948A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 01/21/2009 | EP2016937A1 Formulation of liposomal vesicles in aqueous solutions with tear film characteristics |
| 01/21/2009 | EP2016930A2 A cell therapy method for the treatment of tumors |
| 01/21/2009 | EP2016419A2 Methods for the in vitro screening of compounds inhibiting production of infectious hiv-1 virions |
| 01/21/2009 | EP2016417A1 Biomarkers for endometrial proliferation |
| 01/21/2009 | EP2016187A2 Compositions and methods for enzymatic treatment of lung disorders |
| 01/21/2009 | EP2015782A2 Compositions and methods for modulating gene expression |
| 01/21/2009 | EP2015770A2 Insulin derivative |
| 01/21/2009 | EP2015769A2 Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof |
| 01/21/2009 | EP2015768A1 Methods for treating kidney disorders |
| 01/21/2009 | EP2015767A2 New approach to treat intraocular hypertension |
| 01/21/2009 | EP2015766A1 Cyclised alpha-conotoxin peptides |
| 01/21/2009 | EP2015765A2 Methods amd compositions for treating conditions |
| 01/21/2009 | EP2015744A2 Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling carnitine content in muscle |
| 01/21/2009 | EP2015743A2 Glutadon |
| 01/21/2009 | EP2015741A2 Histone deacetylase inhibitors for the treatment of neurodegeneration |
| 01/21/2009 | EP2015737A1 A process of preparing microspheres for sustained release having improved dispersibility and syringeability |
| 01/21/2009 | EP1583568B1 Process for the preparation of biomedical devices with peptide containing coatings |
| 01/21/2009 | EP1569680B1 Treatment of diabetes |
| 01/21/2009 | EP1517915B1 Prodrugs of excitatory amino acids |
| 01/21/2009 | EP1497323B1 Multiple branch peptide constructions comprising from 2 to 16 branches of the peptide rqgys or from 8 to 16 branches of the peptide rqgy providing from the hiv gp41 glycoprotein |
| 01/21/2009 | EP1487867B1 Modified plasminogen activator inhibitor type-1 and methods based thereon |
| 01/21/2009 | EP1432443B1 Angiotensin peptide-carrier conjugates and uses thereof |
| 01/21/2009 | EP1421106B1 Catalysis of the cis/trans isomerisation of secondary amide peptide compounds |
| 01/21/2009 | EP1399563B1 Moraxella (branhamella) catarrhalis antigens |
| 01/21/2009 | EP1353691B1 Molecular antigen array presenting amyloid beta |
| 01/21/2009 | EP1333036B1 Peg-modified erythropoietin |
| 01/21/2009 | EP1307588B1 Method for diagnosing or determining a risk for psychosis comprising determining an heterozygous mutation of methylenetetrahydrofolate reductase (MTHFR) |
| 01/21/2009 | EP1234880B1 Novel protein tab2 |
| 01/21/2009 | EP1019438B1 Apoptosis-related compounds and their use |
| 01/21/2009 | EP0981352B1 Use of aplidine for the treatment of cardiovascular diseases |
| 01/21/2009 | EP0975760B1 Motilin homologs |
| 01/21/2009 | EP0951466B1 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 01/21/2009 | EP0850053B1 Erythrocytes loaded with s-nitrosothiol and uses therefor |
| 01/21/2009 | CN101351557A Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with RNA virus or DNA virus spike protein |
| 01/21/2009 | CN101351554A Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| 01/21/2009 | CN101351550A Chimaeric fusion protein with superior chaperone and folding activities |
| 01/21/2009 | CN101351475A Interleukin-12p40 variants with improved stability |
| 01/21/2009 | CN101351230A Implantable biocompatible immunoisolatory vehicle for delivery of GDNF |
| 01/21/2009 | CN101351229A Therapeutic method for blood coagulation disorder |
| 01/21/2009 | CN101351221A Outer coat protein PA5158 of pseudomonas aeruginosa |
| 01/21/2009 | CN101351220A Thrombin-free biological adhesive and use thereof as a medicament |
| 01/21/2009 | CN101351219A Stable formulations containing enhancing proportions of gamma- and alpha-interferons |
| 01/21/2009 | CN101351218A Method and use of interferon compositions for the treatment of avian influenza |
| 01/21/2009 | CN101351217A Pharmaceutical compositions for cell therapy of pigmentation disorders |
| 01/21/2009 | CN101351216A Compositions comprising IGBPMA and uses thereof |
| 01/21/2009 | CN101351215A A method of treatment |
| 01/21/2009 | CN101351214A Treatment of neurodegenerative disorders |
| 01/21/2009 | CN101351190A Sodium chloride solution for drug reconstitution or dilution |
| 01/21/2009 | CN101348798A Construction of recombinant adenovirus vector expressing bFGF protein and use of recombinant adenovirus vector for in vivo ear transfection |
| 01/21/2009 | CN101348789A Production of human mutant proteins in human cells by homologous recombination |
| 01/21/2009 | CN101348524A Protein stabilization formulations |
| 01/21/2009 | CN101348521A Aminoacid mimic epitope of human B lymphocyte stimulating factor receptor and use thereof |
| 01/21/2009 | CN101347623A Multifunctional nanodevice platform |
| 01/21/2009 | CN101347615A Method for aggregating acetylcholinergic receptor for stabilizing neuromuscular junction |
| 01/21/2009 | CN101347614A Growth hormone formulations |
| 01/21/2009 | CN101347613A Composition of glucoprotein containing nearly no subunit and preparation method thereof |
| 01/21/2009 | CN101347431A Use of flibanserin in the treatment of sexual disorders |
| 01/21/2009 | CN100453643C Purification method of human glutathione-s-transferase Pi and application of said enzyme |
| 01/21/2009 | CN100453554C Suppressing peptide of heptitis B virus polymerase lymerase protein YMDD functionalized area and its uses |
| 01/21/2009 | CN100453553C Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 01/21/2009 | CN100453115C Self-emulsifying agglomerant of oral polypeptide medicine |
| 01/20/2009 | USRE40624 An isolated nucleic acid encoding the ASKRK polypeptide comprising an amino acid identification sequence #2; nucleotide sequences; expression vector; pancreatic beta host cell. antidiabetic agents; non-insulin dependent diabetes |
| 01/20/2009 | US7479914 A-D converter and A-D convert method |
| 01/20/2009 | US7479552 Type-1 ribosome-inactivating protein |
| 01/20/2009 | US7479551 Enhanced membrane binding affinityl blood coagulation |
| 01/20/2009 | US7479549 Recombinant canine thyroid stimulating hormone and methods of production and use thereof |
| 01/20/2009 | US7479547 Using shuffled viral protein sequences as tool in generating antibodies for diagnosis, prevention and treatment of viral disease |
| 01/20/2009 | US7479545 Used as pharmaceuticals, diagnostics, biosensors and bioreactors |
| 01/20/2009 | US7479544 biological conjugated drug binding with a detectable label, or toxin maytansine and calicheamicin; monoclonal antibody as antiinflammatory agents in the therapeutic treatment and diagnostic detection of immune disorders in mammals; biodrugs |
| 01/20/2009 | US7479543 chimeric antibodies comprising variable domain peptides, DNA codes for the antibodies, expression vectors, host cells and a process of culturing the host cells to produce the monoclonal antibodies, used for immunotherapy; nonimmunogenic |
| 01/20/2009 | US7479542 polymer conjugated drug contains polyethylene glycol covalently attached to the polypeptide; biodrug for treating hepatitis C; new kind of interleukins; fusion proteins |
| 01/20/2009 | US7479541 and fusion proteins with green fluorescent protein, used for modulating cell differentiation and apoptosis, including cell formation of tissues |
| 01/20/2009 | US7479539 Hedgehog fusion proteins |
| 01/20/2009 | US7479538 Improved in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells |
| 01/20/2009 | US7479537 Reagents and methods useful for detecting diseases of the breast |
| 01/20/2009 | US7479536 Chiral, charged peptide nucleic acid oligomers from cyclic monomers |
| 01/20/2009 | US7479484 Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity |
| 01/20/2009 | US7479483 Tumor-targeted drug delivery systems and uses thereof |
| 01/20/2009 | US7479482 For treatment of neurodegenerative disorders |
| 01/20/2009 | US7479481 Treatment of ocular diseases and disorders using lantibiotic compositions |
| 01/20/2009 | US7479478 Human parathyroid hormone modifications, preparation and use |
| 01/20/2009 | US7479376 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics |
| 01/20/2009 | US7479372 Beta-secretase substrates and uses thereof |
| 01/20/2009 | US7479282 Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
| 01/20/2009 | US7479281 Locally administering botulinum toxin powder to a patient using a using a needleless syringe connected to a tank of compressed inert gas, such as helium, for producing a supersonic gas flow; gold, platinum, tungsten or ice crystal carrier; pain is alleviated within 1 to 7 days of administration |
| 01/20/2009 | US7479280 Papilloma virus capsid support comprising chimeric lymphocyte epitope for use in identifying modulators to treat and prevention cell proiferative, autoimmune and viral diseases |
| 01/20/2009 | US7479279 Use of cytokines of the TGF-β superfamily for the treatment, inhibition and/or diagnosis of skin related disorders |
| 01/20/2009 | US7479278 Troponin I polypeptide fragments and uses thereof |
| 01/20/2009 | US7479277 Method for reducing intraocular pressure using integrin-linked kinase inhibitor |
| 01/20/2009 | US7479275 Daily intravenous administration of VEGFR1R2-Fc Delta C1 or coadministration with a cytotoxic, chemotherapeutic or antigrowth agent, while gradually decreasing dosage of the antagonist; colorectal cancer |
| 01/20/2009 | US7479274 Daily intravenous administration of VEGFR1R2-Fc Delta C1 or coadministration with a cytotoxic, chemotherapeutic or antigrowth agent, while gradually decreasing dosage of the antagonist; pancreatic cancer |
| 01/20/2009 | US7479273 Method of administering and using VEGF inhibitors for the treatment of renal cell cancer |
| 01/20/2009 | US7479272 Method of administering and using VEGF inhibitors for the treatment of breast cancer |
| 01/20/2009 | US7479270 Methods and compositions for activating VEGF-D and VEGF-C |
| 01/20/2009 | CA2517245C Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| 01/20/2009 | CA2502856C Intermediates for retroviral protease inhibiting compounds |
| 01/20/2009 | CA2444116C Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| 01/20/2009 | CA2415438C .alpha. crystalline form of perindopril tert-butylamine salt |